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Abstract
Background: 5-allyl-7-gen-difluoromethoxychrysin (AFMC) is a novel synthetic analogue of chrysin that has been
reported to inhibit proliferation in various cancer cell lines. Tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL) is a promising anti-cancer agent.
Methods: The cytotoxicity of A549 and WI-38 cells were determined using colorimetry. Apoptosis was detected by
flow cytometry (FCM) after propidium iodide (PI) fluorescence staining and agarose gel electrophoresis. Caspase
activities were evaluated using enzyme-linked immunosorbent assay (ELISA).The expressions of DR4 and DR5 were
analyzed using FCM and western blot.
Results: Subtoxic concentrations of AFMC sensitize human non-small cell lung cancer (NSCLC) A549 cells to TRAIL-
mediated apoptosis. Combined treatment of A549 cells with AFMC and TRAIL significantly activated caspase-3, -8
and -9. The caspase-3 inhibitor zDEVD-fmk and the caspase-8 inhibitor zIETD-fmk blocked the apoptosis of A549
cells induced by co-treatment with AFMC and TRAIL. In addition, we found that treatment of A549 cells with AFMC
significantly induced the expression of death receptor 5 (DR5). AFMC-mediated sensitization of A549 cells to TRAIL
was efficiently reduced by administration of a blocking antibody or small interfering RNAs against DR5. AFMC also
caused increase of the Sub-G1 cells by TRAIL treatment and increased the expression levels of DR5 in other NSCLC
H460 and H157 cell lines. In contrast, AFMC-mediated induction of DR5 expression was not observed in human
embryo lung WI-38 cells, and AFMC did not sensitize WI-38 cells to TRAIL-induced apoptosis.
Conclusions: AFMC synergistically enhances TRAIL-mediated apoptosis in NSCLC cells through up-regulating DR5
expression.
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Background
Lung cancer is the leading cause of cancer deaths in the
world with over one million cases diagnosed every year.
Multiple options for the treatment of lung cancer have
been described, including surgery, chemotherapy and
radiation; however, therapeutic efficacy is typically tran-
sient and mostly absent with advanced disease [1,2].
Therefore, the need for more rational approaches to
lung cancer therapy is essential.
Chrysin (5, 7-dihydroxyflavone) is a naturally occur-
ring flavonoid possessing a broad range of pharmacolo-
gical activities and is widely found in fruits, vegetables,
honey and propolis [3,4]. Recent studies have shown
that chrysin in diets is a promising biological anti-cancer
agent. Chrysin has been demonstrated to induce apopto-
sis of human myeloid leukemia cells via activation of
caspases and inactivation of Akt [5]. Our previous stu-
dies demonstrated that chrysin and its derivatives exhib-
ited significant anticancer effect against gastric cancer
SGC-7901 cells and colorectal cancer HT-29 cells [6,7].
However, administration of chrysin alone is insufficient.
The combination of chrysin with other anti-cancer
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biological activity of chrysin.
Our previous studies showed that inhibition of prolif-
eration and induction of apoptosis by 5,7-dihydrox-8-
nitrochrysin and 8-bromo-7-methoxychrysin in human
gastric carcinoma SGC-7901 cells and hepatocellular
carcinoma cells, respectively, was stronger than that of
the lead compound chrysin [8,9]. 5-allyl-7-gen-difluoro-
methoxychrysin (AFMC) is another important derivative
of chrysin. We previously reported that AFMC inhibited
the proliferation of the ovarian cancer CoC1 cell line
and hepatocellular carcinoma HepG2 cell line [10,11].
However, whether AFMC possesses antitumor effects on
human non-small cell lung cancer (NSCLC) cells and
the molecular mechanisms of its action remain to be
determined.
Tumor necrosis factor-related apoptosis-inducing
ligand (TRAIL) is a member of the tumor necrosis fac-
tor (TNF) superfamily, which includes potent inducers
of apoptosis in a wide variety of cancer cells [12-14]. In
particular, TRAIL is considered as the most promising
anticancer agent in the TNF superfamily because of its
selective cytotoxicity against tumor cells versus normal
primary cells. TRAIL induces apoptosis in various can-
cer cells through its interaction with death receptor 5
(DR5), which contains a cytoplasmic death domain cap-
able of recruiting apoptosis signaling molecules and
inducing apoptosis [15-21]. However, many tumor cells
are resistant to TRAIL-induced apoptosis [22,23]. Var-
ious cancer therapeutic agents have been demonstrated
to augment TRAIL-induced apoptosis through induction
of DR5 expression [24-30], indicating that DR5 expres-
sion levels might be involved in resistance to TRAIL.
Thus, induction of DR5 expression could enhance cyto-
toxicity and apoptosis mediated by TRAIL.
In this study, we investigated the apoptotic effects of
AFMC in combination with TRAIL on NSCLC cells.
We show for the first time that AFMC synergistically
enhances TRAIL-mediated apoptosis in NSCLC cells
through up-regulating DR5 expression. Thus, our find-
ings raise the possibility that combined use of AFMC
and TRAIL could be a candidate therapy for the treat-
ment of human NSCLC.
Methods
Cell lines and cell culture
Human non-small-cell lung carcinoma cell lines A549,
which possess wild-type p53 [31], were purchased from
China Center for Type Culture Collection (CCTCC,
Wuhan, China). Human lung cancer cell lines H460,
which possess wild-type p53 [31], H157, which express
mutant p53 [31], and human embryo lung WI-38 cells
were purchased from Cell Bank, Chinese Academy of
Sciences (Shanghai, China). A549 and WI-38 cells were
cultured in RPMI-1640 medium with 10% fetal bovine
serum, 100 units/mL penicillin and 100 μg/mL strepto-
mycin (Life Technologies, Inc) at 37°C in a 5% CO2
incubator. H460 and H157 cells were maintained in
DMEM supplemented with 10% bovine calf serum, 1
mmol/L sodium pyruvate, 2 mmol/L L-glutamine and
50 μg/mL penicillin/streptomycin.
Reagents
AFMC was synthesized as previously described [6].
AFMC was dissolved in dimethyl sulfoxide (DMSO),
diluted with phosphate buffer solution (PBS), and pre-
pared at 2 mmol/L in a storage solution after filtration
sterilization. Chrysin was purchased from Sigma (St.
Louis, MO). RPMI-1640 was purchased from Gibco
Company. Fetal bovine serum was from Hangzhou Sijiq-
ing Biological Engineering Materials Co., Ltd. Trypsin
and DMSO was from Amersco Company. The Apopto-
tic DNA Ladder Detection Kit was purchased from Bod-
ataike Company (Beijing, China). Caspase 3 Activity
Detection Kit, Caspase 8 Colorimetric Activity Assay Kit
25, and Caspase 9 Colorimetric Activity Assay Kit were
from Millipore, (Billerica, MA, U.S.A.). Mouse anti-
human DR5 and DR4 monoclonal antibodies were from
Santa Cruz Biotechnology, Inc (Santa Cruz, CA, U.S.A).
Fluorescein isothiocyanate (FITC)-conjugated anti-
mouse IgG was from Zymed Laboratories(South San
Francisco, CA, USA). Mouse IgG1 immunoglobulin was
from DakoCytomation(Glostrup, Denmark). Recombi-
nant human TRAIL was purchased from PeproTech,
Inc. (London, United Kingdom). Lipofectamine 2000
reagent was from Invitrogen Company. DR5/Fc chimera
protein and caspase inhibitors (zDEVD-fmk for caspase-
3, zIETD-fmk for caspase-8 and zLEHD-fmk for cas-
pase-9) were from R&D Systems (Minneapolis, MN).
Lactate dehydrogenase (LDH) release assay
Cells were seeded in 24-well plates at a density of 1.0 ×
10
4 cells/well as previously described [30]. Drugs of dif-
ferent concentrations were added to each well and cul-
tured for 48 h. Supernatants (500 μL) were then
removed from each sample for measurement of LDH
release. The absorbance of the sample was read at 490
nm using an automatic biochemistry analyzer. All treat-
ments and control samples were analyzed in triplicate.
Cytotoxicity (%) was calculated as (A490 of treated
group)/( A490 of positive control group), where the posi-
tive control was the absorbance of cells cultured in
medium containing 100 mmol/L H2O2.
Detection of apoptosis and caspase activity
Apoptosis was detected by flow cytometry (FCM) after
propidium iodide (PI) fluorescence staining as described
previously [32]. DNA ladder bands were determined by
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evaluated using enzyme-linked immunosorbent assay
(ELISA) as previously described [33]. Fold increases in
caspase activity were calculated as (A405 of treated
group)/(A405 of negative control group), where the nega-
tive control was the absorbance of cells cultured in
medium containing only 0.2% DMSO. In the caspase
inhibition assays, cells were pretreated with a caspase-
specific inhibitor (10 μmol/L zDEVD-fmk, zIETD-fmk,
or zLEHD-fmk) for 1 h prior to addition of agents
tested.
Analysis of cell surface receptor expression
Cells were cultured as indicated concentration and for
24 h, and then collected. Five hundred thousand cells
for each receptor analysis were transferred to polystyr-
ene tubes, washed twice with PBS and resuspended in
PBS containing 0.5% BSA (Sigma). A specific monoclo-
nal antibody to either DR5, DR4 or unspecific mouse
IgG1 as isotype control was applied at 5 μg/mL. Cells
were incubated for 20 min with gentle rocking at the
room temperature. Cells were washed twice in PBS and
secondary fluorescein isothiocyanate-conjugated polyclo-
nal goat antibody to mouse IgG1 (1:200 in PBS contain-
ing 0.5% BSA) was added, followed by incubation
protected from light for 30 min with gentle rocking at
the room temperature. Cells were then washed and
resuspended in PBS containing 0.5% BSA. All analysis
was carried out on an EPICS XL flow cytometer (Coul-
ter, Miami, FL) using CellQuest software (Pharmingen
BD Biosciences).
Silencing of DR5 expression using small interfering RNA
(siRNA)
Silencing of DR5 expression in A549 cells was per-
formed as previously described by Wang et al.[ 3 4 ] .
High-purity control (LacZ) and DR5 siRNA oligos were
synthesized by Shanghai Sangon Biotech Co., Ltd and
consisted of 21 base pairs. The sequences are as follows:
DR5, 5’-AAGACCCUUGUGCUCGUUGUC-3’,a n d
LacZ, 5’-AACGUACGCGGAAUACUUCGA-3’.s i R N A
transfection was performed using the Lipofectamine
2000 reagent following the manufacturer’si n s t r u c t i o n s .
Forty-eight hours after transfection, cells were treated
with TRAIL and AFMC alone or in combination for
another 24 h. Gene-silencing efficiency was evaluated by
Western blotting using mouse anti-human DR5 mono-
clonal antibody. Apoptotic rate was measured by FCM
after PI staining and caspase activation was determined
using ELISA.
Western blot analysis
The procedures for preparation of whole cell lysates
and Western blot analysis have been previously
described [35]. Anti-DR5, anti-DR4 and anti-b-actin
antibodies were used as primary antibodies. Signals
were detected using an ECL Advanced Western blot
analysis system (Amersham Pharmacia Biotech Inc.,
Piscataway, NJ, USA).
Statistical analysis
Experimental data in each group were presented as
mean ± SD. Analysis of variance was performed with
SPSS 15.0 software for Windows using one-way
ANOVA and pair-wise comparison with t test. P < 0.05
was considered statistically significant.
Results
Subtoxic concentrations of AFMC sensitize A549 cells to
TRAIL-induced apoptosis
We first performed the LDH release assay to measure
the cytotoxic effects of AFMC and TRAIL alone or in
combination on NSCLC A549 cells compared to that of
the lead compound chrysin. Treatment of A549 cells
with 30 to 1000 ng/mL TRAIL for 24 h induced limited
cytotoxicity (< 15%), suggesting that these cells were
resistant to the cytotoxic effects of TRAIL. Slight cyto-
toxicity (< 20%) was also observed when cells were trea-
ted with 1.0 to 30.0 μmol/L AFMC. However, co-
treatment of A549 cells with TRAIL and AFMC mark-
edly increased the cytotoxic effects of TRAIL in a dose-
dependent manner compared to treatment with TRAIL
or AFMC alone (Figure 1A). As shown in Figure 1B,
similar results were obtained when cells were treated
with 10.0 to 300 μmol/L chrysin (which is equivalent to
10 times the concentration of AFMC). These results
indicated that subtoxic concentrations of AFMC and
chrysin sensitized TRAIL-resistant human NSCLC A549
cells to TRAIL-induced cytotoxicity and that AFMC was
more potent than the lead compound chrysin. Thus, we
focused our study on the effect and mechanism of
AFMC.
We then investigated whether apoptosis was induced
by the combination of AFMC and TRAIL using flow
cytometric analysis to detect increases in hypodiploid
cell populations. Co-treatment of A549 cells with 1.0
μmol/L AFMC and 30 ng/mL TRAIL for 24 h signifi-
cantly induced accumulation of cells in the sub-G1
phase, which increased at 12 h and peaked at 24 h,
whereas treatment with AFMC or TRAIL alone did not
(Figure 1C and 1D). Furthermore, DNA fragmentation
analysis by agarose gel electrophoresis showed a typical
ladder pattern of inter-nucleosomal DNA fragments in
A549 cells co-treated with 1.0 μmol/L AFMC and 30
ng/mL TRAIL, but not in cells treated with AFMC or
TRAIL alone (Figure 1E). Collectively, these results sug-
gested that AFMC stimulated TRAIL-induced apoptosis
in A549 cells.
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Page 3 of 11Activation of caspase-8 is required for induction of
apoptosis in A549 cells by combined treatment with
AFMC and TRAIL
Monasterio et al [36]. reported that flavonoids, includ-
ing chrysin, induced apoptosis via a mechanism that
required the activation of caspase-3 and caspase-8, indi-
cating that chrysin-induced apoptosis could act via a
ligand/receptor-dependent cell death mechanism. There-
fore, we next examined whether caspases were activated
during the induction of apoptosis in A549 cells by the
combined treatment with AFMC and TRAIL. Treatment
of A549 cells with 1.0 μmol/L AFMC alone for 24 h did
not induce activation of caspase-3, -8 or -9. Similarly,
these caspases were not activated in response to treat-
ment of A549 cells with 30 ng/mL TRAIL. In contrast,
co-treatment with AFMC andT R A I Li n d u c e dt h ea c t i -
vation of caspase-3, -8 and -9 (Figure 2A).
To further investigate caspase activation by AFMC
and TRAIL co-treatment, we treated A549 cells with the
caspase-3 inhibitor zDEVD-fmk, the caspase-8 inhibitor
zIETD-fmk and the caspase-9 inhibitor zLEHD-fmk. As
shown in Figure 2B, zDEVD-fmk and zIETD-fmk
reduced the activation of caspase-3 induced by AFMC
and TRAIL, whereas zLEHD-fmk had little effect. Simi-
larly, zIETD-fmk completely blocked caspase-8 activa-
tion, and zDEVD-fmk partially blocked caspase-8,
whereas zLEHD-fmk had no effect (Figure 2B). Likewise,
we found that caspase-9 was activated in cells treated
with AFMC plus TRAIL but not in the presence of
zIETD-fmk or zLEHD-fmk (Figure 2B). Collectively,
these results suggested that AFMC and TRAIL activated
caspase-8 upstream of caspase-9 in A549 cells.
We further examined the role of caspase-8 activated
during apoptosis using the caspase-8 inhibitor zIETD-
fmk. Co-treatment with AFMC and TRAIL induced
activation of caspase-3, which was disrupted by zIETD-
fmk (Figure 2B). zIETD-fmk reversed the AFMC and
TRAIL-induced accumulation of A549 cells in the sub-
G1 phase (Figure 2C). These data indicated that apopto-
sis induced by AFMC and TRAIL co-treatment was
dependent on caspase-8 activation.
AFMC increases the expression of DR5 in A549 cells
We previously reported that AFMC induced apoptosis
in the ovarian cancer CoC1 cell line and human hepato-
cellular carcinoma Hep G2 cell line [11,37]. TRAIL is
Figure 1 Cytotoxic and apoptotic activities of AFMC or TRAIL or both on A549 cells. Figure 1A: A549 cells were treated with AFMC for 30
min and then treated with or without TRAIL for 24 h at the indicated concentrations. Cytotoxicity was assessed by ELISA. Columns, average of
three individual experiments; bars, SD. Figure 1B: A549 cells were treated with chrysin for 30 min and then treated with or without TRAIL for 24
h at the indicated concentrations. Cytotoxicity was assessed by ELISA. Columns, average of three individual experiments; bars, SD. Figure 1C:
A549 cells treated with 1 μmol/L AFMC or 30 ng/mL TRAIL for 24 h or the pretreated with 1 μmol/L AFMC for 30 min followed by 30 ng/mL
TRAIL for 24 h. DNA content of the cells was analyzed by flow cytometry. Columns, average of three individual experiments; bars, SD. a P < 0.05
vs 0.2% DMSO; b P < 0.05 vs 30 ng/mL TRAIL or 1.0 μmol/L AFMC alone. Figure 1D: A549 cells were pretreated with 1.0 μmol/L AFMC for 30
min and then treated with 30 ng/mL TRAIL for the indicated times. DNA content of the cells was analyzed by flow cytometry. Figure 1E: A549
cells were treated as Figure 1C described, fragmented DNA was extracted from treated cells and analyzed on a 2.0% agarose gel.
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trigger apoptotic signaling pathways, and caspase-8 plays
a central role in apoptosis mediated by death recep-
tors [37-39]. To explore the molecular mechanism by
which AFMC enhanced the induction of apoptosis by
TRAIL in A549 cells, we first examined the effect of
AFMC on the expression of DR4 and DR5 by Western
blotting. As shown in Figure 3A, we found that AFMC
treatmemt for 24 h significantly up-regulated DR5
expression in A549 cells in a dose-dependent manner.
The increase in DR5 expression occurred as early as 6 h
after treatment, which preceded the increase in hypodi-
ploid cell populations occurring after 12 h of AFMC
and TRAIL co-treatment (Figure 3B and 1D). In addi-
tion, FCM analysis showed that AFMC increased DR5
protein levels on the surface of A549 cells (Figure 3C).
DR5 expression levels in A549 cells increased in a dose-
dependent manner with AFMC treatment, but DR4
expression levels did not obviously change (Figure 3C).
AFMC enhances TRAIL-induced apoptosis through
upregulation of DR5 in A549 cells
To confirm that induction of apoptosis by the combina-
tion of AFMC and TRAIL occurred through DR5 upre-
g u l a t i o n ,w eu s e dD R 5 / F cc h i m e r ap r o t e i n ,a
pharmacological inhibitor, and DR5 siRNA to block
DR5 expression at the mRNA level, respectively. In cells
transfected with DR5 siRNA, DR5 expression was
reduced to basal levels (Figure 4A). FCM analysis using
PI staining showed that treatment of cells with 1 μg/mL
DR5/Fc or DR5 siRNA reduced the frequency of sub-G1
cells to 7.61 ± 0.32% or 5.47 ± 0.30%, respectively
(Figure 4B), compared to 40.47 ± 2.73% in control
siRNA-transfected cells. Collectively, these results clearly
indicated that decreasing DR5 levels could efficiently
block the apoptosis caused by co-treatment with AFMC
and TRAIL. We also found that AFMC and TRAIL-
induced caspase-8 and -3 activation was efficiently abro-
gated when DR5 expression was attenuated or blocked
by the DR5/Fc chimera protein or DR5 siRNA transfec-
tion (Figure 4C and 4D). These results indicated that
AFMC-mediated sensitization of A549 cells to TRAIL
was dependent on the upregulation of DR5 expression.
Effects of combined treatment with AFMC and TRAIL on
apoptosis and DR5 expression in other NSCLC lines and
in human immortalized embryo lung WI-38 cells
We investigated whether AFMC in combination with
TRAIL induces apoptosis and increases DR5 protein
levels on the surface of other NSCLC cells, including
H460 and H157. Combined use of AFMC with TRAIL
induced the accumulation of sub-G1 population in a
dose-dependent manner in both cell lines (Figure 5A).
The results by FCM analysis shown that AFMC
increased DR5 protein levels dose-dependently on the
surface of H460 and H157 cells, but DR4 expression
levels did not obviously change (Figure 5B). Together,
these findings suggest that the potentiation of TRAIL-
induced apoptosis and upregulation of DR5 expression
by AFMC is not specific to A549 cell line.
To evaluate the selectivity of apoptosis induction of
NSCLC cells by combination treatment with AFMC and
TRAIL, we next examined the cytotoxic effects of
AFMC and TRAIL in human immortalized embryo lung
Figure 2 Effects of AFMC and/or TRAIL on the caspase activities of A549 cells. Figure 2A: Enzymatic activities of caspase -3, -8 and -9 were
determined by incubation of 20 μg of total protein with 200 μmol/L chromogenic substrate (Ac-DEVD-pNA, Ac-IETD-pNA or Ac-LEHD-pNA) in
100 μL of assay buffer for 2 h at 37°C. The release of the chromophore p-nitroanilide (pNA) was monitored spectrophotometrically at 405 nm.
Data are shown as mean ± S.D. (n = 3). a P < 0.05 vs. 0.2% DMSO; b P < 0.05 vs. 30 ng/mL TRAIL or 1.0 μmol/L AFMC alone. Figure 2B: A549
cells were pretreated with 1.0 μmol/L AFMC for 30 min and then treated with 30 ng/mL TRAIL for 24 h in the presence or absence of 10.0
μmol/L caspase inhibitors. Enzymatic activities of caspase -3, -8 and -9 were determined as described above. Data are shown as mean ± S.D. (n
= 3). a P < 0.05 vs. 0.2% DMSO; b P < 0.05 vs. 30 ng/mL TRAIL or 1.0 μmol/L AFMC alone. Figure 2C: A549 cells were treated as described
above. The frequency of cells in the sub-G1 phase was measured using flow cytometry. Data are shown as mean ± S.D. (n = 3). a P < 0.05 vs.
0.2% DMSO; b P < 0.05 vs. pretreatment with caspase inhibitors.
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Page 5 of 11WI-38 cells. Notably, neither TRAIL or AFMC alone
nor in combination was cytotoxic to WI-38 cells (Figure
6A). In addition, the increased frequency of cells in the
sub-G1 phase, activation of caspase-3 and -8 and DNA
fragmentation induced by co-treatment with TRAIL and
AFMC were not observed in WI-38 cells (Figure 6B, C,
D, E) under conditions in which apoptosis was markedly
induced in A549 cells (Figure 1C, D, E). In addition,
AFMC did not induce the expression of DR5 protein in
WI-38 cells (Figure 6F).
Discussion
Flavonoids are a broad class of plant polyphenols that
have important pharmacological effects. Recent studies
have shown that chrysin and its derivatives possess
strong anticancer activities. Methylated polyphenol deri-
vatives have been reported to possess stronger bioactiv-
ities and higher hepatic metabolic stability and intestinal
absorption than the lead compound [40,41], making
these derivatives more favorable than the unmethylated
lead compound for development as potential cancer
chemopreventive agents. Our previous studies showed
that AFMC, a derivative of chrysin, potently inhibited
the proliferation of ovarian cancer CoC1 cells and
human hepatocellular carcinoma HepG2 cells in a dose-
dependent manner [11,42]. In this study, we found that
AFMC sensitized A549 cells to TRAIL-induced apopto-
sis and enhanced the cytotoxic effects of TRAIL but had
little effect on human embryo lung WI-38 cells (Figures
1 and 6). Combined treatment with subtoxic concentra-
tions of AFMC and TRAIL induced caspase-3 and -8
activation and apoptosis of A549 cells (Figure 2). Activa-
tion of caspases plays an important role in apoptosis
triggered by various proapoptotic signals [42,43]. Two
major apoptotic pathways exist: one involving signals
transduced through death receptors and one dependent
on signals from the mitochondria [9,42]. Both pathways
activate the caspase cascade, leading to cleavage of cellu-
lar substrates and the morphological and biochemical
manifestations of apoptosis. The activation of caspase-8
and -9 has been documented to play central roles in
mediating apoptosis through death receptors and the
mitochondrial pathway, respectively [9,42]. However,
caspase-8 can activate caspase-9-mediated apoptotic
pathways via activation or cleavage of Bid protein [42,43].
Therefore, our results suggest that the induction of
apoptosis in A549 cells by AFMC and TRAIL might
involve death signals transduced through death recep-
tors. As expected, we found that AFMC increased the
expression of DR5 in a concentration- and time-
Figure 3 AFMC increases DR5 protein levels in A549 cells. Figure 3A: A549 cells were treated with the indicated concentrations of AFMC for
24 h, and DR5 levels were measured by Western blotting. b-actin was used as a loading control. Figure 3B: A549 cells were treated with 1.0
μmol/L AFMC for the indicated time, and DR5 levels were measured by Western blotting. b-actin was used as a loading control. Figure 3C: A549
cells were treated with the indicated concentrations of AFMC for 24 h, DR5 and DR4 protein levels on the surface of A549 cells were determined
using flow cytometry. Mouse IgG1 was used as an isotype control.
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In addition, we demonstrated that AFMC enhanced
TRAIL-induced apoptosis in human lung cancer A549
cells through upregulation of DR5. Collectively, our
findings could yield new insights into maximizing the
efficiency of human lung carcinoma treatments while
minimizing side effects to normal tissues.
Lung cancer represents the leading cause of cancer
deaths in the world [1,2]. NSCLC accounts for approxi-
mately 75% of lung cancers [44]. About 50% of NSCLC
Figure 4 Effects of DR5/Fc and DR5 siRNA on AFMC-induced DR5 expression and AFMC/TRAIL-induced apoptosis. Figure 4A: A549 cells
were transfected with LacZ siRNA or siRNA against DR5 followed by treatment with 1.0 μmol/L AFMC for 24 h. DR5 levels were measured by
Western blotting. b-actin was used as a loading control. Figure 4B: A549 cells were preincubated with 1.0 μg/mL DR5-specific blocking chimera
antibody or transfected with siRNAs, incubated for 24 h, and then treated with or without 1.0 μmol/L AFMC for 30 min followed by treatment
with 30 ng/mL TRAIL for 24 h. The frequency of cells in the sub-G1 phase was measured using flow cytometry. Data are shown as mean ± S.D.
(n = 3). aP < 0.05 vs. 0.2% DMSO; bP < 0.05 vs. combined treatment. Figure 4C: A549 cells were treated as described above. Enzymatic activity of
caspase-3 was determined by incubation of 20 μg of total protein with 200 μM of Ac-DEVD-pNA in 100 μL of assay buffer for 2 h at 37°C. pNA
release was monitored spectrophotometrically at 405 nm. Data are shown as mean ± S.D. (n = 3). aP < 0.05 vs. 0.2% DMSO; bP < 0.05 vs.
combined treatment. Figure 4D: A549 cells were treated as described above. Enzymatic activity of caspase-8 was determined by incubation of 20
μg of total protein with 200 μM of Ac-IETD-pNA in 100 μL of assay buffer for 2 h at 37°C. pNA release was monitored spectrophotometrically at
405 nm. Data are shown as mean ± S.D. (n = 3). aP < 0.05 vs. 0.2% DMSO; bP < 0.05 vs. combined treatment.
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Page 7 of 11Figure 5 Effects of AFMC and/or TRAIL on apoptosis and DRs expression of H460 and H157 cells. Figure 5A: Cells were treated with 1.0
μmol/L AFMC or 30 ng/mL TRAIL for 24 h or the pretreated with 1.0 μmol/L AFMC for 30 min followed by 30 ng/mL TRAIL for 24 h. DNA
content of the cells was analyzed by flow cytometry. Columns, average of three individual experiments; bars, SD. a P < 0.05 vs. 0.2% DMSO; b P
< 0.05 vs. 30 ng/mL TRAIL or 1.0 μmol/L AFMC alone. Figure 5B: Cells were treated with the indicated concentrations of AFMC for 24 h, DR5 and
DR4 protein levels on the surface of A549 cells were determined using flow cytometry. Mouse IgG1 was used as an isotype control.
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Page 8 of 11Figure 6 AFMC neither induce expression of DR5 nor enhance TRAIL-induced apoptosis in WI-38 cells.F i g u r e6 A :W I - 3 8c e l l sw e r e
treated with AFMC for 30 min and then treated with TRAIL for 24 h at the indicated concentrations. Cytotoxicity was assessed by ELISA.
Columns, average of three individual experiments; bars, SD. a P < 0.05 vs. 0.2% DMSO; c P < 0.05 vs. 1.0 μmol/L AFMC. Figure 6B: WI-38 cells
were treated with 1.0 μmol/L AFMC, 30 ng/mL TRAIL or the pretreated with 1.0 μmol/L AFMC for 30 min followed by 30 ng/mL TRAIL for 24 h.
DNA content of the cells was analyzed by flow cytometry. Figure 6C: WI-38 cells were treated as described above. The enzymatic activity of
caspase-3 was determined by incubation of 20 μg total protein with 200 μM of Ac-DEVD-pNA in 100 μL of assay buffer for 2 h at 37°C. pNA
release was monitored spectrophotometrically at 405 nm. Figure 6D: WI-38 cells were treated as described above. The enzymatic activity of
caspase-8 was determined by incubation of 20 μg of total protein with 200 μM of Ac-IETD-pNA in 100 μL of assay buffer for 2 h at 37°C. pNA
release was monitored spectrophotometrically at 405 nm. Data are shown as mean ± S.D. (n = 3). Figure 6E: WI-38 cells were treated as
described above. Fragmented DNA was extracted from the treated cells and analyzed on a 2.0% agarose gel. Figure 6F: WI-38 cells were treated
with the indicated concentrations of AFMC for 24 h, and DR5 levels were assessed by Western blotting. b-actin was used as a loading control.
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Page 9 of 11patients are initially diagnosed with advanced or meta-
static disease, and the treatment of choice is palliative
chemotherapy. Apoptosis induction is one of the major
objectives of modern cancer therapy, for which an
important goal is to specifically induce apoptosis in
malignant tumor cells but not in normal cells. For this
reason, TRAIL has recently received much attention
because it preferentially kills tumor cells while leaving
normal cells unaffected. However, a considerable num-
ber of tumors are resistant to TRAIL-induced apoptosis
[17,21]. Various conventional chemotherapeutic agents
have been demonstrated to synergistically augment
TRAIL-induced apoptosis through induction of DR5
expression. In this regard, AFMC is an attractive agent
for inducing DR5 expression and sensitizing TRAIL-
resistant A549 cells to TRAIL.
Our study has important implications in cancer treat-
ment. As mentioned above, AFMC enables to overcome
the resistance to TRAIL in NSCLC. Furthermore, more
than half of all malignant tumors possess an inactivating
mutation in the p53 gene and p53 modulates the sensi-
tivity to conventional anticancer agents [45,46].
Although H157 cells harbored inactivated p53 [32],
combined treatment with AFMC and TRAIL is also use-
ful for p53-deficient tumor cells.
Activation of death receptor pathway is a new strategy
for targeted therapy of cancer. Our previous study
demonstrate AFMC induced apoptosis of human hepato-
cellular carcinoma cells via inhibition of NF-B. Studies
by Srivastava et al. shown that MS-275, a histone deace-
tylase (HDAC) inhibitors, could sensitize TRAIL-resis-
tant breast cancer xenografts through the involvement of
both cell-extrinsic and cell-intrinsic pathways of apopto-
sis[47] and resveratrol regulates the expression of
FOXO’s target genes such as Bim, TRAIL, DR4, DR5,
cyclin D1 and p27/KIP1 [48,49]. However, how AFMC
induces DR5 upregulation and enhances TRAIL-induced
apoptosis in NSCLC cells need to be further investigated.
Clinically, resistance to apoptosis is a major obstacle in
chemotherapeutic treatments of cancers. The ability of
AFMC to sensitize A549 cells to TRAIL-induced apoptosis
at subtoxic concentrations makes AFMC a potentially
effective preventative and/or therapeutic agent against
NSCLC. However, the potential clinical implications of
our studies will depend on whether or not AFMC can be
safely administered to patients in high enough doses to be
pharmacologically active. Oral flavonoids cannot be uti-
lized in the clinic because of poor bioavailability because
of rapid metabolism in the liver and intestinal wall. How-
ever, Walle et al[41]. reported that dimethoxyflavone
(DMF) was clearly detected in plasma with a peak concen-
tration of 2.5 ± 0.8 μM (mean ± SEM) at 1 h after gavage
(5 mg/kg each) to rats. In that study, the area under the
plasma concentration-time curve was 58.8 μg ￿ ml
-1 ￿ min.
DMF was also clearly detected in the liver, lung and kid-
ney tissues with concentrations in the liver exceeding
those in the plasma by as much as seven-fold (16.5 ± 5
μM) 1 h after administration. The liver, which showed the
highest accumulation of DMF, might be a site where DMF
exerts its greatest activity. Therefore, additional in vivo
studies are needed to evaluate the applicability of AFMC
as a chemopreventive and/or therapeutic agent for cancer.
Conclusions
We have shown that AFMC induces the expression of
DR5 and enhances the TRAIL-induced apoptosis in
human A549 lung cancer cells. Although further
research is required to dissect the underlying mechan-
isms and evaluate the potency of AFMC and TRAIL co-
treatment in a nude mouse model, collectively, these
results raise the possibility that combined treatment
with TRAIL and AFMC could be a promising candidate
therapeutic for human lung cancer.
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